🟢 Regeneron Pharmaceuticals is trading 6.26% up in pre-market after third-quarter EPS topped consensus

Regeneron Pharmaceuticals is trading at $870.00, up 6.26% in pre-market after third-quarter earnings topped consensus.

• Revenue rose 36% to $5.12 billion; non-GAAP EPS was $20.07, above the supplied $16.19 consensus. Sanofi collaboration revenue climbed 68% to $2.72 billion, helping drive results.
• The release cited strong portfolio execution and FDA approval of Pasatru. With the broader market weak, company-specific results are the clearer catalyst.